EC145, is not only about
and they will get approval in EU and us
but it suits, of which Merck will pay all costs, lots of big market and important threatments
EC20 can be used all over the place, not sure if ECYT wants to licence, but it can
Tubulysin is huge, and confident in rest of pipeline.
I know BIO stock with just 20% of potential trading at market cap of $ 3bln, don't forget market cap is still low, also $200 mln in cash, but I think it will go step by step.
But do not be surprised this trading 24 months from now at $100+
Sentiment: Strong Buy